Therefore, tumor MGMT promoter methylation renders cancer cells susceptible to the cell damaging effects of drug regimens utilizing alkylating agents [116,180] (see also Lessons learned from the DNA methylation biomarker MGMT). This evidence concerns the gene MGMT and cancer.